Invivyd Announces $20 Million to $25 Million Improvement in Projected 2024 Year-End Cash Position

Rhea-AI Summary

Invivyd, Inc. (Nasdaq: IVVD) has announced a significant improvement in its projected 2024 year-end cash position by $20-25 million, expecting to end the year with at least $75 million in cash and cash equivalents. The company achieved these improvements through resource realignment to focus on the commercial launch of PEMGARDA™ and the discovery of novel monoclonal antibodies. Despite eliminating fourteen full-time positions, Invivyd remains positive about its 2024 revenue projections.

Positive

• Significant improvement in projected 2024 year-end cash position by $20-25 million.

• Resource realignment to focus on the commercial launch of PEMGARDA™ and discovery of novel monoclonal antibodies.

• Expecting to end 2024 with at least $75 million in cash and cash equivalents.

• Anticipating 2024 PEMGARDA net product revenue in the range of $150 million to $200 million.

Negative

• Elimination of fourteen full-time positions in connection with the changes.

Insights

Financial Analyst

The announcement from Invivyd, Inc. regarding its improved year-end cash position for 2024 signifies a strategic realignment that seems to have been executed with operational efficiency in mind. The reallocation of resources, specifically towards the commercial launch of PEMGARDA™ and novel monoclonal antibody candidates, reflects a prioritized investment in the company's most promising assets.

From a financial perspective, bolstering the balance sheet by an additional $20 million to $25 million provides a more substantial financial cushion. This is likely to enhance investor confidence, particularly in the biopharmaceutical sector where cash runway is closely monitored as an indicator of a company's ability to sustain operations until profitability. Assuming a conservative burn rate, the updated projection of at least $75 million could extend the company's operational feasibility beyond 2024, a important factor for investors assessing the long-term viability of their investment.

However, the elimination of fourteen full-time positions could indicate a cost-cutting measure that might impact team morale and operational capabilities in the short term. While net product revenue projections for PEMGARDA remain robust, in the range of $150 million to $200 million, investors will be keen to monitor the execution of the commercial launch and any subsequent market penetration metrics that can validate these projections.

Biotech Market Analyst

Invivyd's focus on its cash position is particularly pertinent within the biotech industry, where runway and resource allocation can make or break a company's success. Realignment towards commercialization and discovery underlines the company's transition from a development-stage to a commercial-stage entity, which is often a key inflection point for biotech companies.

The emphasis on PEMGARDA™, presumably a flagship product, suggests confidence in its market potential and expected contribution to revenue growth. For shareholders, the progression of novel monoclonal antibodies is equally significant, given the high stakes of innovation in the biotech industry. It's the potential for groundbreaking treatments that typically drives valuations in this sector, balanced against the inherent risk of clinical and regulatory hurdles. Investors should appreciate the dual strategy of launching an existing product while fueling the discovery pipeline.

The real test for Invivyd will be in translating these strategic adjustments into tangible financial performance. The upcoming Q1 financial report will likely shed light on early commercial traction for PEMGARDA™ and provide clarity on how effectively the company is deploying its resources. Details on clinical operations, manufacturing and control savings will be pertinent for assessing the efficiency of cost optimization efforts.

• Improvements realized through comprehensive resource realignment ensuring robust investment in the commercial launch of PEMGARDA^TM and the discovery of novel monoclonal antibodies
  
• Company now expects to end 2024 with at least $75 million in cash and cash equivalents, an update to previously issued financial guidance

WALTHAM, Mass., April 30, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to protection from serious viral infectious diseases, today announced that following a comprehensive strategic review, the company is improving its projected 2024 year-end cash position by approximately $20 million to $25 million. Invivyd now expects to end 2024 with at least $75 million in cash and cash equivalents.

“The Executive Committee of the Board of Directors has been working very closely with the management team to ensure that we are investing the company’s resources in the areas that have the greatest potential to deliver appreciable benefits for patients and shareholders,” said Marc Elia, Chairman of the Invivyd Board of Directors. “Following a comprehensive strategic review which was conducted over the past several weeks, we were able to reallocate resources to support the launch of PEMGARDA™, bolster our ability to deliver novel pipeline monoclonal antibody candidates, and further strengthen our balance sheet going forward. We look forward to sharing more details on our financials and our commercial progress when we report Q1 results in May.” 

The improvements were primarily achieved through cash optimization in clinical operations and chemistry, manufacturing and controls (CMC). Fourteen full-time positions were eliminated in connection with the changes. Invivyd continues to anticipate 2024 PEMGARDA net product revenue in the range of $150 million to $200 million.

About PEMGARDA

PEMGARDA™ (pemivibart) is a half-life extended investigational monoclonal antibody (mAb). PEMGARDA was engineered from adintrevimab, Invivyd’s investigational mAb that has a robust safety data package and provided evidence of clinical efficacy in a global Phase 2/3 clinical trial for the prevention of COVID-19. PEMGARDA has demonstrated in vitro neutralizing activity in pseudotyped virus-like particle and authentic virus neutralization assays against major SARS-CoV-2 variants, including JN.1. PEMGARDA targets the SARS-CoV-2 spike protein receptor binding domain (RBD), thereby inhibiting virus attachment to the human ACE2 receptor on host cells.

PEMGARDA (pemivibart) injection (4500 mg), for intravenous use is an investigational mAb that has not been approved, but has been authorized for emergency use by the U.S. FDA under an EUA for the pre-exposure prophylaxis (prevention) of COVID-19 in adults and adolescents (12 years of age and older weighing at least 40 kg) who have moderate-to-severe immune compromise due to certain medical conditions or receipt of certain immunosuppressive medications or treatments and are unlikely to mount an adequate immune response to COVID-19 vaccination. Recipients should not be currently infected with or have had a known recent exposure to an individual infected with SARS-CoV-2. PEMGARDA is not authorized for use for treatment of COVID-19 or post-exposure prophylaxis of COVID-19. Anaphylaxis has been observed with PEMGARDA and the PEMGARDA Fact Sheet for Healthcare Providers includes a boxed warning for anaphylaxis. The most common adverse events (all grades, incidence ≥2%) observed in participants who have moderate-to-severe immune compromise treated with PEMGARDA included systemic and local infusion-related or hypersensitivity reactions, upper respiratory tract infection, viral infection, influenza-like illness, fatigue, headache, and nausea. For additional information, please see the PEMGARDA full product Fact Sheet for Healthcare Providers, including important safety information and boxed warning.

To support the EUA for PEMGARDA, an immunobridging approach was used to determine if PEMGARDA may be effective for pre-exposure prophylaxis of COVID-19. Immunobridging is based on the serum virus neutralizing titer-efficacy relationships identified with other neutralizing human mAbs against SARS-CoV-2. This includes adintrevimab, the parent mAb of pemivibart, and other mAbs that were previously authorized for EUA. There are limitations of the data supporting the benefits of PEMGARDA. Evidence of clinical efficacy for other neutralizing human mAbs against SARS-CoV-2 was based on different populations and SARS-CoV-2 variants that are no longer circulating. Additionally, the variability associated with cell-based EC₅₀ value determinations, along with limitations related to pharmacokinetic data and efficacy estimates for the mAbs in prior clinical trials, impact the ability to precisely estimate protective titer ranges.

The emergency use of PEMGARDA is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of drugs and biological products during the COVID-19 pandemic under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization revoked sooner.

About Invivyd

Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to protection from serious viral infectious diseases, beginning with SARS-CoV-2. The company’s proprietary INVYMAB™ platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid, serial generation of new monoclonal antibodies (mAbs) to keep pace with evolving viral threats. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for its first mAb in a planned series of innovative antibody candidates. Visit https://invivyd.com/ to learn more.

Cautionary Note Regarding Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “could,” “expects,” “intends,” “potential,” “projects,” and “future” or similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements include statements concerning, among other things, the company’s plans regarding a comprehensive resource realignment and the anticipated benefits thereof; the company’s anticipated 2024 PEMGARDA net product revenue and the company’s projected 2024 year end cash and cash equivalents balance; the potential of PEMGARDA as a mAb for pre-exposure prophylaxis (prevention) of COVID-19 in certain adults and adolescents (12 years of age and older weighing at least 40 kg) with moderate-to-severe immune compromise; the company’s plans and expectations related to the commercialization of PEMGARDA; the company’s ongoing research and clinical development efforts; the design of the company’s INVYMAB platform approach to facilitate the rapid, serial generation of new mAbs to keep pace with evolving viral threats; the company’s expectation that PEMGARDA is the first mAb in a planned series of innovative antibody candidates; and other statements that are not historical fact. The company may not actually achieve the plans, intentions or expectations disclosed in the company’s forward-looking statements and you should not place undue reliance on the company’s forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the company’s actual results to differ materially from the results described in or implied by the forward-looking statements, including, without limitation: the company’s ability to realize the anticipated benefits of its comprehensive resource realignment; how long the EUA granted by the FDA for PEMGARDA will remain in effect and whether the EUA is revoked or revised by the FDA; the company’s ability to maintain and expand sales, marketing and distribution capabilities to successfully commercialize PEMGARDA; changes in expected or existing competition; the timing and progress of the company’s discovery, preclinical and clinical development activities; the uncertainties and timing of the regulatory authorization or approval process, and available development and regulatory pathways for authorization or approval of the company’s product candidates; changes in the regulatory environment; unexpected safety or efficacy data observed during preclinical studies or clinical trials; the ability to maintain a continued acceptable safety, tolerability and efficacy profile of PEMGARDA or any other product candidate following regulatory authorization or approval; the predictability of clinical success of the company’s product candidates based on neutralizing activity in preclinical studies; the risk that results of preclinical studies or clinical trials may not be predictive of future results, and interim data are subject to further analysis; the company’s reliance on third parties with respect to virus assay creation and product candidate testing and with respect to its clinical trials; variability of results in models used to predict activity against SARS-CoV-2 variants; whether PEMGARDA or any other product candidate is able to demonstrate and sustain neutralizing activity against major SARS-CoV-2 variants, particularly in the face of viral evolution; the complexities of manufacturing mAb therapies; the company’s dependence on third parties to manufacture, label, package, store and distribute clinical and commercial supplies of its product candidates; whether the company is able to provide sufficient commercial supply of PEMGARDA to meet market demand; whether the company can obtain and maintain third-party coverage and adequate reimbursement for PEMGARDA or any other product candidate; the company’s ability to leverage its INVYMAB platform approach to facilitate the rapid, serial generation of new mAbs to keep pace with evolving viral threats; any litigation and other proceedings or government investigations relating to the company; the company’s ability to continue as a going concern; and whether the company has adequate funding to meet future operating expenses and capital expenditure requirements. Other factors that may cause the company’s actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading “Risk Factors” in the company’s Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission (SEC), and in the company’s other filings with the SEC, and in its future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this press release are made as of this date, and Invivyd undertakes no duty to update such information whether as a result of new information, future events or otherwise, except as required under applicable law.

This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.

Contacts:

Media Relations
(781) 208-1747
media@invivyd.com

Investor Relations
(781) 208-1747
investors@invivyd.com

FAQ

What is the stock symbol of Invivyd, Inc. mentioned in the press release?

The stock symbol of Invivyd, Inc. mentioned in the press release is IVVD.

How much improvement is projected in Invivyd's 2024 year-end cash position?

Invivyd expects an improvement of $20-25 million in its projected 2024 year-end cash position.

What is the expected range of 2024 PEMGARDA net product revenue mentioned in the press release?

Invivyd anticipates 2024 PEMGARDA net product revenue in the range of $150 million to $200 million.

How many full-time positions were eliminated by Invivyd, Inc. in connection with the changes mentioned in the press release?

Fourteen full-time positions were eliminated by Invivyd, Inc. in connection with the changes mentioned in the press release.